Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Harvard Bioscience
  4. Financial Statements
  5. Income Statement
Harvard Bioscience logo
Harvard Bioscience HBIO
$ 8.15 0.36%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

Harvard Bioscience Income Statement 2025-2008 | HBIO

Brief overview of financial performance at Harvard Bioscience

The conclusions below are based on five years of reported results. Revenue reported by Harvard Bioscience was $102 million at the beginning of the period and $86.5 million at the end. The cumulative result was −15.2%, corresponding to roughly −3.3% per year. The decline points to a contraction in the scale of the business.

At the gross-profit level, the result moved from 58 million dollars to 49.9 million dollars, a change of −14%. There was no major divergence between sales and cost of revenue. The gross margin was 56.8% at the start and 57.7% at the end. Gross profitability remained broadly stable.

The five-year EBITDA result moved by −889.7%: from $5.9 million to −$46.8 million. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from 5.8% to −54.1%. The business retained less EBITDA from each unit of revenue.

Net income moved from −7.8 million dollars at the start to −56.7 million dollars at the end. The period ended with a larger loss than it began with.

Market value was 179 million dollars at the start and 20.9 million dollars at the end. The valuation did not keep pace with the reported progress.

Financial takeaway

Signs of deterioration dominate the five-year picture. The constructive conclusion rests on a stable gross margin. The overall view is constrained by limited revenue growth, declining net profitability and lower investor confidence. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Harvard Bioscience

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

 20.9 M 20.5 M 188 M 109 M 218 M 179 M 113 M 122 M 163 M 99.2 M 99.8 M 168 M 137 M 108 M 87.6 M 762 M 742 M -

Shares

 44.4 M 43.5 M 42.4 M 41.4 M 40.3 M 38.6 M 37.8 M 36.5 M 34.8 M 34.2 M 33.6 M 32.2 M 30.4 M 28.8 M 28.5 M 29 M 29.6 M -

Historical Prices

 0.47 0.47 4.43 2.64 5.4 4.39 3.24 4.02 4.7 2.8 2.75 5.46 4.88 4.36 3.15 26.3 25 37.8

Net Income

 -56.7 M -12.4 M -3.42 M -9.52 M -288 K -7.81 M -4.69 M -2.92 M -865 K -4.31 M -19 M 2.36 M -1.83 M 2.37 M 3.81 M 19 M 7.23 M -

Revenue

 86.6 M 94.1 M 112 M 113 M 119 M 102 M 116 M 121 M 102 M 105 M 109 M 109 M 105 M 111 M 109 M 108 M 85.8 M -

Cost of Revenue

 36.6 M 39.4 M 46.2 M 52.5 M 51.3 M 44.1 M 51.9 M 57.6 M 38.2 M 56.1 M 59.9 M 59.3 M 57.5 M 58.8 M 58.7 M 56.4 M 44.1 M -

Gross Profit

 49.9 M 54.8 M 66.1 M 60.8 M 67.7 M 58 M 64.3 M 63.2 M 47.6 M 48.4 M 48.7 M 49.3 M 47.7 M 52.4 M 50.3 M 51.8 M 41.7 M -

Operating Income

 -48.6 M -6.21 M 1.89 M -6.93 M 2.07 M 221 K 377 K 984 K -635 K -3 M -1.71 M 6.62 M 1.54 M 7.83 M 8.4 M 10.2 M 8.06 M -

Interest Expense

 -2.66 M -325 K -227 K 302 K -666 K -806 K -469 K 5.37 M 713 K 642 K 854 K 990 K 955 K 584 K 752 K 677 K 277 K -

EBITDA

 -46.8 M -4.48 M 3.37 M -5.48 M 3.85 M 5.93 M 7.58 M 6.37 M 2.34 M 1.59 M 1.89 M 9.41 M 6.28 M 6.23 M 9.29 M 14.1 M 9.26 M -

Operating Expenses

 98.5 M 61 M 64.2 M 67.8 M 65.6 M 57.8 M 62.5 M 62.2 M 47.7 M 49.6 M 49.6 M 42.5 M 44 M 48.9 M 43.7 M 41.6 M 33.6 M -

General and Administrative Expenses

 17.7 M 21.5 M 22.8 M 24.5 M 24.3 M 23.5 M 22.8 M 21.4 M 18.6 M 21 M 19.8 M 16.8 M 19.9 M 19.7 M 18.1 M 17.7 M 15.1 M -

All numbers in USD currency

Quarterly Income Statement Harvard Bioscience

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 4.43 M 4.47 M - 44.6 M 44.3 M 44.1 M 44.1 M 43.6 M 43.5 M 43.4 M 43.4 M 42.7 M 42.4 M 42.1 M 42.1 M 41.6 M 41.3 M 41.2 M 41.1 M 40.8 K 40.2 K 39.8 M 39.4 M 38.9 K 38.5 K 38.3 M 38.2 M 38 M 37.7 M 37.6 M 37.4 M 36.9 M 36.1 M 35.5 M 35 M 34.8 M 34.7 M 34.6 M 35 M 34.3 M 34.1 M 34 M 34 M 33.9 M 33.6 M 32.9 M 32.6 M 32.3 M 32 M 32 M 31.6 M 30.6 M 30.1 M 29.8 M 29.4 M 28.8 M 28.8 M 28.7 M 28.5 M 28.5 M 28.4 M 28.4 M

Net Income

 -2.28 M -3.42 M - -1.23 M -2.28 M -50.3 M - -4.8 M -2.93 M -4.69 M - -1.24 M -980 K 622 K - -3.4 M 2.44 M -6.88 M - -170 K -410 K -669 K - -1.1 M -1.58 M -4.52 M 550 K -2.62 M -247 K -2.37 M 2.86 M -256 K -1.46 M -4.06 M 999 K -417 K -381 K -1.07 M -1.32 M -1.64 M -713 K -636 K -17.1 M -847 K 349 K -1.4 M -19 K 633 K 1.02 M 1.02 M -756 K -984 K -186 K 96 K 1.2 M -133 K 774 K 529 K 738 K 28 K 1.37 M 1.68 M

Revenue

 20.4 M 20.8 M - 20.6 M 20.4 M 21.8 M - 22 M 23.1 M 24.5 M - 25.4 M 28.8 M 30 M - 26.9 M 29.2 M 28.8 M - 29.7 M 29.2 M 27 M - 24 M 23.3 M 23.8 M 31 M 27.4 M 29.6 M 28.2 M 33.9 M 28.6 M 31.5 M 26.8 M 21.6 M 18.7 M 19 M 18.1 M 26.4 M 25 M 26.1 M 27 M 28.4 M 25.7 M 28.8 M 25.8 M 30.4 M 25.4 M 27 M 27 M 27.9 M 25.1 M 26.1 M 26.1 M 28.2 M 26.1 M 28.5 M 28.3 M 29 M 26.4 M 27.1 M 26.3 M

Cost of Revenue

 8.92 M 8.51 M - 8.57 M 8.92 M 9.59 M - 9.2 M 9.88 M 9.74 M - 10.6 M 12.1 M 11.6 M - 14.8 M 12.6 M 12.6 M - 13.4 M 12.8 M 11.6 M - 10.5 M 9.45 M 10.8 M 13.7 M 12.4 M 13.6 M 12 M 15.1 M 12.8 M 16.2 M 13.5 M 10.6 M 9.22 M 9.88 M 8.51 M 14.3 M 13.3 M 14.5 M 14 M 15.4 M 14 M 16.2 M 14.3 M 16.5 M 14 M 14.7 M 14.7 M 15.8 M 13.8 M 14 M 13.8 M 14.9 M 14.1 M 14.9 M 14.9 M 15.8 M 14.5 M 14.4 M 13.9 M

Gross Profit

 11.5 M 12.2 M - 12 M 11.5 M 12.2 M - 12.8 M 13.2 M 14.8 M - 14.7 M 16.7 M 18.3 M - 12.2 M 16.6 M 16.2 M - 16.3 M 16.4 M 15.4 M - 13.5 M 13.9 M 13 M 17.2 M 15 M 16 M 16.2 M 18.7 M 15.8 M 15.4 M 13.3 M 11 M 9.5 M 9.07 M 9.58 M 12.1 M 11.7 M 11.7 M 12.9 M 12.9 M 11.7 M 12.6 M 11.5 M 13.9 M 11.4 M 12.3 M 12.3 M 12 M 11.3 M 12.1 M 12.3 M 13.4 M 12 M 13.6 M 13.4 M 13.2 M 11.9 M 12.8 M 12.4 M

Operating Income

 -819 K -1.17 M - 197 K -819 K -49.7 M - -1.87 M -2.07 M -2.28 M - -933 K 796 K 1.75 M - -3.76 M 4 M -6.71 M - 548 K 58 K -239 K - 182 K 556 K -3.27 M 1.63 M -1.36 M 228 K -120 K 1.74 M 890 K -382 K -1.27 M 374 K -390 K -269 K -350 K -1.12 M -813 K -840 K -221 K 113 K -775 K 99 K -1.15 M 2.12 M 1.42 M 1.74 M 1.74 M -949 K 414 K 746 K 1.33 M 2.14 M 1.16 M 2.47 M 2.06 M 1.39 M 220 K 2.52 M 1.95 M

Interest Expense

 -434 K -405 K - -365 K -644 K -324 K - -518 K -181 K -142 K - 45 K -372 K 432 K - -179 K -62 K 78 K - -130 K -313 K -34 K - -392 K -191 K 111 K - 1.35 M 1.38 M 1.4 M - 1.46 M 1.48 M 894 K - 189 K 180 K 163 K - 141 K 180 K 164 K - 204 K 215 K 222 K - 239 K 248 K 248 K - 276 K 245 K 130 K - 147 K 152 K 147 K - 216 K 192 K 195 K

EBITDA

 343 K -731 K - 1.05 M 343 K -49.2 M - -540 K -738 K -1.88 M - 428 K 2.18 M 2.08 M - -2.19 M 5.45 M -6.33 M - 2.01 M 1.52 M 206 K - 1.64 M 1.54 M -2.79 M 1.63 M 132 K 1.2 M 418 K 1.74 M 2.36 M 669 K -771 K 374 K 619 K 390 K -44 K -1.12 M 360 K -31 K 164 K 113 K 382 K 868 K -786 K 2.12 M 2.34 M 2.35 M 2.35 M -949 K 1.4 M 1.42 M 1.68 M 2.14 M 2.09 M 3.1 M 2.38 M 1.39 M 1.19 M 3.21 M 2.26 M

Operating Expenses

 12.4 M 13.4 M - 11.8 M 12.4 M 61.9 M - 14.6 M 15.3 M 17.1 M - 15.7 M 15.9 M 16.6 M - 15.9 M 12.6 M 22.9 M - 15.8 M 16.3 M 15.7 M - 13.3 M 13.3 M 16.3 M 15.6 M 16.3 M 15.7 M 16.3 M 17 M 14.9 M 15.7 M 14.5 M 10.6 M 9.89 M 9.34 M 9.93 M 13.2 M 12.5 M 12.5 M 13.2 M 12.8 M 12.5 M 12.5 M 12.6 M 11.7 M 10 M 10.5 M 10.5 M 13 M 10.9 M 11.3 M 10.9 M 11.3 M 10.8 M 11.1 M 11.3 M 11.8 M 11.7 M 10.3 M 10.4 M

General and Administrative Expenses

 4.26 M 4.7 M - 4.18 M 4.26 M 5.18 M - 5.04 M 5.69 M 5.96 M - 5.81 M 5.35 M 6.33 M - 6.32 M 5.98 M 6.32 M - 5.46 M 6.4 M 6.33 M - 5.4 M 5.67 M 6.76 M - 6.6 M 4.81 M 5.8 M - 4.66 M 5.26 M 5.38 M - 4.32 M 4.11 M 4.79 M - 4.78 M 5.24 M 5.95 M - 5 M 4.92 M 4.83 M - 4.13 M 4 M 4 M - 4.65 M 4.36 M 4.22 M - 4.83 M 4.9 M 4.86 M - 4.56 M 4.21 M 4.36 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Harvard Bioscience (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical instruments industry

Issuer Price % 24h Market Cap Country
BioLife Solutions BioLife Solutions
BLFS
 		$ 38.61 3.51 % $ 1.84 B usaUSA
Atrion Corporation Atrion Corporation
ATRI
 		- - $ 810 M usaUSA
Alcon Alcon
ALC
 		$ 63.87 1.38 % $ 31.5 B schweizSchweiz
Becton, Dickinson and Company Becton, Dickinson and Company
BDX
 		$ 188.89 0.81 % $ 54.3 B usaUSA
AtriCure AtriCure
ATRC
 		$ 57.3 0.76 % $ 2.74 B usaUSA
Baxter International Baxter International
BAX
 		$ 24.8 0.46 % $ 12.7 B usaUSA
electroCore electroCore
ECOR
 		$ 8.2 0.06 % $ 69.6 K usaUSA
Glaukos Corporation Glaukos Corporation
GKOS
 		$ 167.89 1.44 % $ 9.6 B usaUSA
NeuroMetrix NeuroMetrix
NURO
 		- 5.05 % $ 9.02 M usaUSA
AngioDynamics AngioDynamics
ANGO
 		$ 11.05 1.38 % $ 459 M usaUSA
Haemonetics Corporation Haemonetics Corporation
HAE
 		$ 121.11 0.67 % $ 5.71 B usaUSA
InfuSystem Holdings InfuSystem Holdings
INFU
 		$ 13.6 0.74 % $ 281 M usaUSA
iRhythm Technologies iRhythm Technologies
IRTC
 		$ 106.05 0.97 % $ 3.39 B usaUSA
Intuitive Surgical Intuitive Surgical
ISRG
 		$ 420.24 0.52 % $ 150 B usaUSA
Repro Med Systems Repro Med Systems
KRMD
 		$ 3.11 3.67 % $ 144 M usaUSA
LeMaitre Vascular LeMaitre Vascular
LMAT
 		$ 82.62 1.31 % $ 1.87 B usaUSA
Milestone Scientific Milestone Scientific
MLSS
 		$ 0.34 1.34 % $ 27.9 M usaUSA
Merit Medical Systems Merit Medical Systems
MMSI
 		$ 87.16 0.18 % $ 5.16 B usaUSA
Nephros Nephros
NEPH
 		$ 3.52 0.56 % $ 37.4 M usaUSA
Envista Holdings Corporation Envista Holdings Corporation
NVST
 		$ 22.82 0.75 % $ 3.83 B usaUSA
Pulse Biosciences Pulse Biosciences
PLSE
 		$ 46.32 7.66 % $ 3.12 B usaUSA
ICU Medical ICU Medical
ICUI
 		$ 162.69 0.09 % $ 4.01 B usaUSA
Pro-Dex Pro-Dex
PDEX
 		$ 59.82 0.04 % $ 193 B usaUSA
Repligen Corporation Repligen Corporation
RGEN
 		$ 178.2 1.58 % $ 10 M usaUSA
ResMed ResMed
RMD
 		$ 235.29 0.11 % $ 34.2 B usaUSA
Retractable Technologies Retractable Technologies
RVP
 		$ 0.59 0.8 % $ 17.7 M usaUSA
STAAR Surgical Company STAAR Surgical Company
STAA
 		$ 21.84 1.58 % $ 1.08 B usaUSA
STERIS plc STERIS plc
STE
 		$ 217.26 0.64 % $ 21.3 B usaUSA
Stereotaxis Stereotaxis
STXS
 		$ 1.05 2.7 % $ 95.5 M usaUSA
Teleflex Incorporated Teleflex Incorporated
TFX
 		$ 123.29 0.35 % $ 5.5 B usaUSA
Utah Medical Products Utah Medical Products
UTMD
 		$ 74.79 0.11 % $ 242 M usaUSA
OraSure Technologies OraSure Technologies
OSUR
 		$ 3.71 0.51 % $ 273 M usaUSA
West Pharmaceutical Services West Pharmaceutical Services
WST
 		$ 374.65 0.77 % $ 27.1 B usaUSA
DENTSPLY SIRONA DENTSPLY SIRONA
XRAY
 		$ 8.44 0.29 % $ 1.68 B usaUSA
CRH Medical Corporation CRH Medical Corporation
CRHM
 		- - $ 282 M usaUSA
Cantel Medical Corp. Cantel Medical Corp.
CMD
 		- -1.18 % $ 3.4 B usaUSA
The Cooper Companies The Cooper Companies
COO
 		$ 54.88 0.53 % $ 10.9 B usaUSA
Microbot Medical Microbot Medical
MBOT
 		$ 0.99 0.49 % $ 45.3 M israelIsrael
Luminex Corporation Luminex Corporation
LMNX
 		- - $ 1.75 B usaUSA
Akers Biosciences, Inc. Akers Biosciences, Inc.
AKER
 		- -9.52 % $ 20.6 M usaUSA
Antares Pharma, Inc. Antares Pharma, Inc.
ATRS
 		- - $ 955 M usaUSA
Hill-Rom Holdings, Inc. Hill-Rom Holdings, Inc.
HRC
 		- -0.05 % $ 10.3 B usaUSA
Varian Medical Systems, Inc. Varian Medical Systems, Inc.
VAR
 		- -0.02 % $ 16.3 B usaUSA
Ekso Bionics Holdings Ekso Bionics Holdings
EKSO
 		- - $ 28.6 M usaUSA
Isoray Isoray
ISR
 		- 0.03 % $ 108 M usaUSA
Masimo Corporation Masimo Corporation
MASI
 		- - $ 9.59 B usaUSA
Predictive Oncology Predictive Oncology
POAI
 		- - $ 31.1 M usaUSA